Skip to content
Therapy But Better – Lifestyle
Author:
Abivax
Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis
May 26, 2026
Abivax Announces Results of its May 11, 2026 Annual General Meeting
May 11, 2026
Abivax Announces Repurchase of Royalty Certificates and Pricing of $45M (€38.5M) Offering of American Depositary Shares
May 5, 2026
Abivax to Present Data on Obefazimod at Digestive Disease Week®
April 22, 2026
Abivax Annual Ordinary and Extraordinary General Meeting of May 11, 2026 Availability of the Preparatory Documents
April 20, 2026
Abivax Publishes Financial Reports with the French and U.S. Securities Regulatory Agencies
April 1, 2026
Abivax Announces Full Year 2025 Financial Results and Provides Business Updates
March 24, 2026